Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir prophylaxis versus pre-emptive CMV prevention after heart transplantation
2008-006980-35Phase 3Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Mar 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of valganciclovir, everolimus, mycophenolate mofetil and cyclosporine in cytomegalovirus disease (CMV), coronary vasculopathy and Cardiac Rejection (4 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Started Mar 2009; status: completed.
02
Drugs
valganciclovireverolimusmycophenolate mofetilcyclosporine
03
Conditions
cytomegalovirus disease (CMV)coronary vasculopathyCardiac Rejection
Beyond the preview
Go deeper on 2008-006980-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006980-35.